Compare ACCL & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCL | AIDX |
|---|---|---|
| Founded | 2009 | N/A |
| Country | Hong Kong | United States |
| Employees | 22 | N/A |
| Industry | Professional Services | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 19.5M |
| IPO Year | N/A | N/A |
| Metric | ACCL | AIDX |
|---|---|---|
| Price | $1.40 | $1.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.0K | ★ 53.2K |
| Earning Date | 05-20-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.13 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.23 | $1.26 |
| 52 Week High | $5.00 | $14.09 |
| Indicator | ACCL | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 30.50 |
| Support Level | $1.32 | N/A |
| Resistance Level | $1.57 | $1.66 |
| Average True Range (ATR) | 0.06 | 0.13 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 44.19 | 36.57 |
Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.